Correction: Analysis of miRNA profiles identified miR-196a as a crucial mediator of aberrant PI3K/AKT signaling in lung cancer cells

PDF  |  How to cite

Oncotarget. 2022; 13:755-755. https://doi.org/10.18632/oncotarget.28237

Metrics: PDF 107 views  |   ?  

Ilaria Guerriero1, Daniela D’Angelo2, Pierlorenzo Pallante2, Mafalda Santos1, Marianna Scrima1, Donatella Malanga3, Carmela De Marco3, Maria Ravo4, Alessandro Weisz4, Carmelo Laudanna3, Michele Ceccarelli1,5, Geppino Falco1,6, Antonia Rizzuto7, and Giuseppe Viglietto1,3

1Biogems.c.ar.l., Istituto di Ricerche Genetiche “Gaetano Salvatore”, Ariano Irpino, Avellino, Italy
2Istituto per l’Endocrinologia e l’Oncologia Sperimentale, IEOS-CNR, c/o Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università “Federico II” of Napoli, Napoli, Italy
3Dipartimento di Medicina Sperimentale e Clinica, Università Magna Graecia of Catanzaro, Italy
4Laboratorio di Medicina Molecolare e Genomica, Dipartimentodi Medicina e Chirurgia, Università di Salerno, Baronissi, Italy
5Department of Biological and Environmental Studies, Università del Sannio, Benevento, Italy
6Dipartimento di Biologia, Università degli Studi di Napoli Federico II, Complesso Universitario Monte S.Angelo, Napoli, Italy
7Dipartimento di Scienze Mediche e Chirurgiche, Università Magna Graecia of Catanzaro, Italy

Published: May 25, 2022

Copyright: © 2022 Guerriero et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 6B, the H460-SCR-EV image (upper left panel) contains accidental overlaps from the H460-shAKT1-miR-196a image (lower right panel). The corrected Figure 6B, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:19172–19191. DOI: https://doi.org/10.18632/oncotarget.13432

Figure 6: MiR-196a regulates migration and tumorigenicity of NSCLC cells. (B) Boyden chamber migration assay of control NCI-H460-SCR-EV, NCI-H460-shAKT1-EV, NCI-H460-SCR-antimiR-196a and NCI-H460-shAKT1-miR-196a cells. The graph represents the mean number (±SD) of migrated cells/field. Representative images of migrated NCI-H460 and derivative cells. Magnification 10×; p < 0.001.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28237